Telomir Pharmaceuticals, Inc. Common Stock
Symbol: TELO (NASDAQ)
Company Description:
Telomir Pharmaceuticals Inc is a pioneering preclinical-stage pharmaceutical company which leads the advancement of age-reversal science. The Company is focused on developing Telomir-1, a novel small molecule designed to lengthen and protect telomeres-the protective DNA end caps of chromosomes that are crucial to cellular aging. As humans and animals age, telomeres naturally shorten, with metal reactivity accelerating this process, increasing the risk of degenerative and age-related diseases. By addressing the underlying causes of aging at the cellular level, Telomir aims to tackle the root of these conditions rather than simply treating their symptoms. Telomir is conducting ongoing preclinical research into Progeria, diabetes, cancer, Alzheimer's disease, osteoarthritis, and others.
- Today's Open: $2.185
- Today's High: $2.295
- Today's Low: $2.172
- Today's Volume: 821.57K
- Yesterday Close: $2.29
- Yesterday High: $2.44
- Yesterday Low: $2.04
- Yesterday Volume: 3.42M
- Last Min Volume: 1.40K
- Last Min High: $2.2
- Last Min Low: $2.2
- Last Min VWAP: $2.2
- Name: Telomir Pharmaceuticals, Inc. Common Stock
- Website: https://www.telomirpharma.com
- Listed Date: 2024-02-09
- Location: MIAMI, FL
- Market Status: Active
- CIK Number: 0001971532
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $68.16M
- Round Lot: 100
- Outstanding Shares: 29.76M
- Asset Type: CS
Filing Date | Filing Type | Format |
---|---|---|
2025-07-23 | 8-K | View |
2025-07-22 | 8-K | View |
2025-07-17 | 8-K | View |
2025-06-18 | 8-K | View |
2025-06-11 | 8-K | View |
2025-06-10 | 3 | View |
2025-06-05 | 8-K | View |
2025-06-02 | 8-K | View |
2025-05-30 | 4 | View |
2025-05-29 | 8-K | View |
2025-05-21 | 8-K | View |
2025-05-21 | 8-K | View |
2025-05-15 | 8-K | View |
2025-05-14 | 10-Q | View |
2025-05-07 | 8-K | View |
2025-03-19 | 8-K | View |
2025-02-28 | EFFECT | View |
2025-02-26 | CORRESP | View |
2025-02-25 | 8-K | View |
2025-02-20 | 8-K | View |